Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience - Takeaways - MDSpire

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

  • By

  • Sara A. Scott

  • Ellen M. Marin

  • Kathryn T. Maples

  • Nisha S. Joseph

  • Craig C. Hofmeister

  • Vikas A. Gupta

  • Madhav V. Dhodapkar

  • Jonathan L. Kaufman

  • Sagar Lonial

  • Ajay K. Nooka

  • December 20, 2023

  • 0 min

Share

  • 1

    Teclistamab is a bispecific antibody approved for relapsed/refractory multiple myeloma, showing a 63% overall response rate in clinical trials.

  • 2

    Prophylactic tocilizumab reduced the incidence of cytokine release syndrome (CRS) from 73.3% to 26.3% in patients receiving teclistamab.

  • 3

    The median duration of CRS in the prophylactic cohort was 1 day, with most events being grade 1, indicating reduced severity.

  • 4

    Prophylactic tocilizumab did not increase the incidence of grade 3 or 4 neutropenia compared to the MajesTEC-1 trial.

  • 5

    These findings support the safe outpatient administration of teclistamab while effectively managing CRS in heavily pre-treated patients.

Original Source(s)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

  • by Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

  • December 20, 2023

Related Content

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside